A pill you can swallow with breakfast — or without it — that takes twelve percent of your body weight off over 36 weeks. That is the number coming out of a randomized phase II trial of aleniglipron published in Nature Medicine, and the fact that it is a pill matters every bit as much as the percentage.
Until now, every GLP-1 drug that has had a cultural moment arrived with a needle attached. Semaglutide, sold as Ozempic and Wegovy, is a peptide, and peptides get injected. Aleniglipron is not a peptide at all.
Why a small molecule changes the math
Aleniglipron is a small-molecule drug, chemically synthesized rather than grown, and it is being developed as an obesity treatment taken by mouth. That single structural distinction ripples through nearly everything patients complain about with the current generation.
Injectable GLP-1s can work extremely well. Getting hold of them is a different story. They require refrigeration, they require needles, and manufacturing them at the volume demand actually calls for is both difficult and expensive.
Small-molecule versions could sidestep some of that, said Robert Kushner, MD, ’82 GME, professor emeritus of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at Northwestern and a co-author of the study. They are oral, and producing them in bulk may be easier.
“The difference with aleniglipron is it’s a small molecule, which means it’s chemically made and could be taken with or without food. Most medications we take, whether it’s aspirin or blood pressure medicine, are small molecules. They’re chemicals that you make structurally, and because of that you can potentially combine them with other medications,” Kushner said.
That final clause is the part to circle. Combination therapy is far easier to design around a chemical than around a refrigerated peptide.
What 230 adults actually did for 36 weeks
The trial was double-blind and placebo-controlled, conducted across 38 U.S. medical centers, and enrolled 230 adults who had obesity or overweight. Their average age was 50.
Participants were randomized into three dose groups: 45, 90 or 120 milligrams. A single oral dose daily, stepped up every four weeks, or placebo. Thirty-six weeks in total.
The dose-response curve behaved the way you would want it to. Average change in body weight from baseline came in at -9.0 percent on 45 milligrams, -10.7 percent on 90 milligrams and -12.1 percent on 120 milligrams. Placebo moved -0.5 percent.
The side effects nobody’s surprised by
Gastrointestinal problems turned up, as they always do with this class of drug. Across the treatment groups they were generally mild to moderate, and they became less frequent as the study progressed.
Discontinuation reached 10.4 percent of participants overall. Researchers reported no cases of drug-induced liver injury — a specific thing to check for, and a specific thing to have found nothing of.
The findings, Kushner said, support advancing alenglipron as an obesity treatment and testing how well it performs in an upcoming phase III trial.
“We didn’t find any concerns; no new safety signals. We found a dose that seems to be effective, and the dose escalation will be slowed down further as we go into phase III trial to increase tolerability,” Kushner said.
Read that carefully. Slowing the escalation in phase III is an admission that climbing to 120 milligrams on a four-week ladder was rougher than the team would like, even with side effects tapering off over time.
What this is and isn’t
This is a phase II safety trial in 230 people, not a head-to-head against semaglutide, and nobody has run that comparison here. Structure Therapeutics supported the work.
The figure to watch in phase III is not the weight-loss percentage. It is whether a gentler dose ramp can hold on to that -12.1 percent while pulling the 10.4 percent dropout rate down, because a pill people quit taking is worth less than a shot they don’t.